The venture capital firm conducted a 12-month exhaustive search and found no dedicated venture fund for telehealth, Sid Jawahar, its founder and managing partner said. Swiftarc Telehealth will focus initially on obesity care, mental and behavioral health, and pediatrics.

Georgia lawmakers will consider a bill that could force the state’s Medicaid managed-care insurers to repay millions of dollars if their spending on medical care doesn’t reach a certain threshold.

TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating within Foresite Labs and it now has $40 million to finance its research into this new realm of biology.

The current landscape heading into 2022 will keep pharmacy benefits under the microscope. Plan sponsors will evaluate their PBM’s pricing model to determine if their contract will deliver predictable costs, more opportunities for increased savings and improved care for their members.

Palliative care must be the standard of care for all who have been diagnosed with progressive, advanced, and terminal illnesses. Never should we hear the phrase, “I’m sorry, there’s nothing more I can do,” when physicians encounter the failure of a curative course of therapy.

Andrew Bott, Director of Talent Acquisition in EMEA & APAC countries at Medidata, shared his insights on hiring trends in this sector, in response to emailed questions.

Aequitas Partners Managing Director Tim Gordon shared what he’s seeing in the job market.

Employers can now submit open positions to the Jobs section on the MedCity News website.

Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines. According to CEO Jeff Finer, the startup is kicking off a second golden age of GPCR drug development.

Betty Chow, a Los Angeles resident, had a cervical disc replaced in August 2020 at […]

Six years in, the subtext of the scheduled reimbursements increase for 2022 is that CCM has proven to be an essential part of the care continuum, particularly in the wake of the Covid-19 pandemic, and has real value for patients, providers, and payers.

As virtual specialty care options continue to expand and access remains limited to dermatologists, Smart Health Innovation Lab announced this week that the platform, which allows people to do a full-body skin screening using a smartphone app, has joined the healthcare technology accelerator.

Mantra Health, which provides digital mental health tools for university students, raised $22M in a Series A funding round to offer its evidence-based teletherapy and psychiatric services to patients with long term mental health issues.

Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t reflective of the true value of the therapy the company is hoping to commercialize.

Gilead Sciences did not disclose details about the safety concern that led to an FDA partial clinical hold on five studies evaluating its cancer drug, magrolimab. But this experimental cancer immunotherapy introduces a safety risk that’s a known problem for all drugs in this class.

The Texas Medical Association (TMA) filed a brief on Monday to further oppose the ruling on the No Suprises Act that currently allows aribtrators to use the average in-network rate to determine out-of-network cost.

Lagging behavioral health and substance use treatment benefits are a major barrier to care, especially for those already struggling to get help. The Departments of Labor, Health and Human Services and the Treasury shared their findings with Congress Tuesday.

Sierra Oncology myelofibrosis drug momelotinib achieved the main and secondary goals of a pivotal test and the biotech now plans to seek FDA approval. Sierra acquired momelotinib from Gilead Sciences after that company stopped work on the drug due to mixed results in Phase 3 testing.

Basic organic chemicals used for the preparation of new medications cost over 54.8% more than they did 12 months ago. Further, with schools and daycare facilities either going fully remote and/or closed, many parents and caregivers had to stay at home, eliminating their availability for study participation.

Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.